Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study
Indexado
WoS WOS:000928268200001
Scopus SCOPUS_ID:85145644512
DOI 10.1016/S2666-7568(22)00247-1
Año 2023
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background: The triglyceride glucose (TyG) index is an easily accessible surrogate marker of insulin resistance, an important pathway in the development of type 2 diabetes and cardiovascular diseases. However, the association of the TyG index with cardiovascular diseases and mortality has mainly been investigated in Asia, with few data available from other regions of the world. We assessed the association of insulin resistance (as determined by the TyG index) with mortality and cardiovascular diseases in individuals from five continents at different levels of economic development, living in urban or rural areas. We also examined whether the associations differed according to the country's economical development. Methods: We used the TyG index as a surrogate measure for insulin resistance. Fasting triglycerides and fasting plasma glucose were measured at the baseline visit in 141 243 individuals aged 35–70 years from 22 countries in the Prospective Urban Rural Epidemiology (PURE) study. The TyG index was calculated as Ln (fasting triglycerides [mg/dL] x fasting plasma glucose [mg/dL]/2). We calculated hazard ratios (HRs) using a multivariable Cox frailty model with random effects to test the associations between the TyG index and risk of cardiovascular diseases and mortality. The primary outcome of this analysis was the composite of mortality or major cardiovascular events (defined as death from cardiovascular causes, and non-fatal myocardial infarction, or stroke). Secondary outcomes were non-cardiovascular mortality, cardiovascular mortality, all myocardial infarctions, stroke, and incident diabetes. We also did subgroup analyses to examine the magnitude of associations between insulin resistance (ie, the TyG index) and outcome events according to the income level of the countries. Findings: During a median follow-up of 13·2 years (IQR 11·9–14·6), we recorded 6345 composite cardiovascular diseases events, 2030 cardiovascular deaths, 3038 cases of myocardial infarction, 3291 cases of stroke, and 5191 incident cases of type 2 diabetes. After adjusting for all other variables, the risk of developing cardiovascular diseases increased across tertiles of the baseline TyG index. Compared with the lowest tertile of the TyG index, the highest tertile (tertile 3) was associated with a greater incidence of the composite outcome (HR 1·21; 95% CI 1·13–1·30), myocardial infarction (1·24; 1·12–1·38), stroke (1·16; 1·05–1·28), and incident type 2 diabetes (1·99; 1·82–2·16). No significant association of the TyG index was seen with non-cardiovascular mortality. In low-income countries (LICs) and middle-income countries (MICs), the highest tertile of the TyG index was associated with increased hazards for the composite outcome (LICs: HR 1·31; 95% CI 1·12–1·54; MICs: 1·20; 1·11–1·31; pinteraction=0·01), cardiovascular mortality (LICs: 1·44; 1·15–1·80; pinteraction=0·01), myocardial infarction (LICs: 1·29; 1·06–1·56; MICs: 1·26; 1·10–1·45; pinteraction=0·08), stroke (LICs: 1·35; 1·02–1·78; MICs: 1·17; 1·05–1·30; pinteraction=0·19), and incident diabetes (LICs: 1·64; 1·38–1·94; MICs: 2·68; 2·40–2·99; pinteraction <0·0001). In contrast, in high-income countries, higher TyG index tertiles were only associated with an increased hazard of incident diabetes (2·95; 2·25–3·87; pinteraction <0·0001), but not of cardiovascular diseases or mortality. Interpretation: The TyG index is significantly associated with future cardiovascular mortality, myocardial infarction, stroke, and type 2 diabetes, suggesting that insulin resistance plays a promoting role in the pathogenesis of cardiovascular and metabolic diseases. Potentially, the association between the TyG index and the higher risk of cardiovascular diseases and type 2 diabetes in LICs and MICs might be explained by an increased vulnerability of these populations to the presence of insulin resistance. Funding: Full funding sources are listed at the end of the paper (see Acknowledgments).

Revista



Revista ISSN
2666-7568

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Geriatrics & Gerontology
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Lopez-Jaramillo, Patricio Hombre Universidad de Santander - Colombia
Univ Santander - Colombia
2 Gomez-Arbelaez, Diego Hombre Universidad de Santander - Colombia
Univ Santander - Colombia
3 Martinez-Bello, Daniel Hombre Universidad de Santander - Colombia
Univ Santander - Colombia
4 Hori, M. Hombre Philippine General Hospital - Filipinas
Philippine Gen Hosp - Filipinas
5 AlHabib, Khalid F. Hombre King Saud University - Arabia Saudí
King Saud Univ - Arabia Saudí
6 Avezum, Álvaro Hombre Hospital Alemao Oswaldo Cruz - Brasil
Hosp Alemao Oswaldo Cruz - Brasil
7 Barbarash, Olga L. Mujer Kuzbass Cardiology Center SB RAS - Rusia
Fed State Budgetary Inst Res Inst Complex Issues - Rusia
8 Chifamba, Jephat - University of Zimbabwe - Zimbabue
Univ Zimbabwe - Zimbabue
9 Diaz, Maria Luz Mujer Estudios Clínicos Latinoamérica, Argentina - Argentina
Estudios Clin Latinoamer - Argentina
Inst Cardiovasc Rosario - Argentina
10 Gulec, Sadi Hombre Ankara Üniversitesi - Turquía
Ankara Univ - Turquía
11 Ismail, Noorhassim Mujer Faculty of Medicine, UKM - Malasia
Univ Kebangsaan Malaysia - Malasia
12 Iqbal, Romaina Mujer The Aga Khan University - Pakistán
Aga Khan Univ - Pakistán
13 Kelishadi, R. Mujer Isfahan Cardiovascular Research Center, Isfahan UMS - Iran
Isfahan Univ Med Sci - Iran
14 Khatib, Rasha Mujer Advocate Aurora Research Institute - Estados Unidos
Birzeit University - Palestina
Advocate Aurora Hlth - Estados Unidos
Birzeit Univ - Palestina
15 LANAS-ZANETTI, FERNANDO TOMAS Hombre Universidad de La Frontera - Chile
16 Levitt, Naomi S. Mujer University of Cape Town - República de Sudáfrica
UNIV CAPE TOWN - República de Sudáfrica
17 Li, Yang - Fuwai Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College - China
Peking Union Med Coll - China
Chinese Acad Med Sci - China
18 Mohan, V. - Madras Diabetes Research Foundation - India
Dr Mohans Diabet Special Ctr - India
Madras Diabet Res Fdn - India
19 Mony, Prem K. Mujer St. John's Medical College - India
St Johns Med Coll & Res Inst - India
St. John's National Academy Of Health Sciences India - India
20 Puri, Raman Hombre Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval - Canadá
UNIV LAVAL - Canadá
Queen's University, School of Medicine - Canadá
Queens Univ - Canadá
21 Rosengren, Annika Mujer Sahlgrenska Akademin - Suecia
Univ Gothenburg - Suecia
Sahlgrens Univ Hosp - Suecia
22 Soman, Biju - Mysore Medical College - India
Med Coll - India
Sree Chitra Tirunal Inst Med Sci & Technol - India
Mysore Medical College And Research Institute - India
23 Wang, Chuangshi - Fuwai Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College - China
Peking Union Med Coll - China
Chinese Acad Med Sci - China
24 Wang, Yang - Fuwai Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College - China
Peking Union Med Coll - China
Chinese Acad Med Sci - China
25 Puri, Raman Hombre Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval - Canadá
UNIV LAVAL - Canadá
Queen's University, School of Medicine - Canadá
Queens Univ - Canadá
26 Yusuf, Rita Mujer Independent University, Bangladesh - Bangladesh
Independent Univ - Bangladesh
27 Yusufali, Afzal Hussein Hombre Tamani Foundation - Tanzania
Tamani Fdn - Tanzania
28 Zatonska, Katarzyna Mujer Wroclaw Medical University - Polonia
Wroclaw Med Univ - Polonia
29 Rangarajan, Sumathy Mujer Population Health Research Institute, Ontario - Canadá
MCMASTER UNIV - Canadá
30 Yusuf, Salim Hombre Population Health Research Institute, Ontario - Canadá
MCMASTER UNIV - Canadá

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Novartis
GlaxoSmithKline
Population Health Research Institute
Ontario Ministry of Health and Long-Term Care
King Pharma
Servier
Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario
Boehringer Ingelheim [Germany]
Sanofi-Aventis [Canada]
AstraZeneca [Canada]
Sanofi-Aventis [France]
Boehringer Ingelheim [Canada]
Hamilton Health Sciences Research Institute
Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario SPOR Support Unit

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
The PURE study is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research's Strategy for Patient Oriented Research through the Ontario SPOR Support Unit, and the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. Further details on the funding and participating countries and institutions, and on collaborating staff, are shown in the appendix (pp 15-22).

Muestra la fuente de financiamiento declarada en la publicación.